Jeff Yass’s Vor Biopharma VOR Stock Holding History

Jeff Yass’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$303K	Sell	16,454 -216,154	-93%	-$3.27M	﹤0.01%	11022
2026 Q1	$4.15M	Buy	232,608 +217,789	+1,470%	+$3.07M	﹤0.01%	4589
2025 Q4	$194K	Buy	+14,819	New	+$276K	﹤0.01%	10906
2025 Q2	–	Sell	-19,215	Closed	-$170K	–	13801
2025 Q1	$276K	Buy	19,215 +13,464	+234%	+$323K	﹤0.01%	10242
2024 Q4	$128K	Buy	+5,751	New	+$95.3K	﹤0.01%	11141
2024 Q3	–	Sell	-12,358	Closed	-$247K	–	13130
2024 Q2	$247K	Buy	12,358 +11,029	+830%	+$357K	﹤0.01%	9882
2024 Q1	$63K	Sell	1,329 -1,850	-58%	-$81.2K	﹤0.01%	11463
2023 Q4	$143K	Buy	3,179 +537	+20%	+$22.2K	﹤0.01%	11016
2023 Q3	$112K	Sell	2,642 -833	-24%	-$45.2K	﹤0.01%	10821
2023 Q2	$215K	Sell	3,475 -13,073	-79%	-$1.19M	﹤0.01%	10139
2023 Q1	$1.78M	Buy	16,548 +14,153	+591%	+$1.57M	﹤0.01%	5398
2022 Q4	$319K	Buy	+2,395	New	+$237K	﹤0.01%	8946
2022 Q3	–	Sell	-2,654	Closed	-$264K	–	14202
2022 Q2	$264K	Buy	+2,654	New	+$272K	﹤0.01%	9907
2022 Q1	–	Sell	-618	Closed	-$144K	–	14064
2021 Q4	$144K	Buy	+618	New	+$178K	﹤0.01%	11840

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Jeff Yass's VOR Position: Q2 2026 in Review

Jeff Yass reduced its Vor Biopharma (VOR) stake by 93% in Q2 2026, selling an estimated $3.27M and leaving 16,454 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #11022.

Jeff Yass first reported a position in VOR in Q4 2021 and has held it in 14 quarters since. The position peaked at $4.15M in Q1 2026. 101 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Jeff Yass held 16,454 shares of Vor Biopharma worth $303K as of Q2 2026.
Jeff Yass sold 216,154 Vor Biopharma shares in Q2 2026, an estimated $3.27M.
Vor Biopharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11022 holding.
Jeff Yass first reported a position in Vor Biopharma in Q4 2021 and has held it in 14 quarters since.
Jeff Yass's Vor Biopharma position peaked at $4.15M in Q1 2026.
101 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.